Applications of (S)-1-Boc-3-(Aminomethyl)Pyrrolidine in Industrial Manufacturing

As a direct producer of (S)-1-Boc-3-(Aminomethyl)Pyrrolidine, we supply this chiral intermediate to diverse industrial segments demanding high-purity enantiomers for specialized synthesis. Our material plays a crucial role in multiple sectors, serving as a key building block for advanced manufacturing in pharmaceuticals, agrochemicals, peptide chemistry, and chemical research for process scale-up.

1. Chiral Intermediate for Antiviral and Central Nervous System (CNS) Pharmaceuticals

Our material acts as a foundation compound in the synthesis of chiral active pharmaceutical ingredients (APIs), especially those targeting CNS and antiviral therapies. Medicinal chemists and process engineers employ it for enantioselective construction of pyrrolidine-containing drug molecules, where precise stereochemistry governs therapeutic profiles. The compound’s protected amine group permits selective deprotection and further transformation under GMP production settings, supporting rigorous impurity control and batch reproducibility. Our strict supply chain ensures traceability and compliance throughout custom API development.

Industry compliance standards

• ICH Q7A Good Manufacturing Practice
• EU GMP Part II (APIs)
• US FDA 21 CFR Part 211
• USP, EP monographs as applicable

Typical usage ratio

• Used at 0.4–1.5 molar equivalents per final API batch, ratio adjusted by the specific synthetic pathway and scale of API production

Downstream process integration

• Introduced during early-stage chiral amine formation; incorporated through amide coupling, reductive amination, or ring expansion; followed by Boc deprotection post-coupling

Final product types

• Chiral APIs for CNS treatments (e.g., pyrrolidine-based drug candidates)
• Intermediates for HIV, HCV, or anti-influenza agents; finished oral and injectable dosage forms

2. Peptide and Peptidomimetic Synthesis

Fine chemical manufacturers and biotech companies utilize our raw material as a building block for the synthesis of non-proteinogenic amino acid segments and peptidomimetics. The Boc-protected aminomethyl pyrrolidine scaffold allows site-selective peptide bond formation compatible with both solution and solid-phase synthesis. The stereochemistry supports high-fidelity construction of secondary-motif peptides, which are often used in the development of enzyme inhibitors, receptor ligands, and novel therapeutic modalities.

Industry compliance standards

• ICH Q11 (Development and Manufacture of Drug Substances)
• ISO 9001:2015 (Quality Management for chemical production)
• REACH (Registration, Evaluation, Authorisation and Restriction of Chemicals) compliance for handling/procurement

Typical usage ratio

• Standard loading: 1.0–1.1 equivalents per coupling reaction; actual quantity guided by peptide sequence and resin loading

Downstream process integration

• Intake during protected amino acid step for peptide elongation; introduced either manually in solution phase or via automated peptide synthesizer; Boc group maintained until final global deprotection

Final product types

• Research peptides
• Investigational peptide drugs
• Custom peptidomimetic ligands supplied to pharmaceutical and life science R&D

3. Agrochemical Chiral Intermediate Manufacturing

Producers of advanced crop protection agents apply this compound in syntheses demanding chiral switch or asymmetric center introduction. The protected aminomethyl pyrrolidine core assists process chemists in creating stereochemically pure intermediates that lead to more selective, less persistent agroactive agents. Downstream, this structural motif enters into active ingredient scaffolds through substitution or coupling reactions, helping companies meet evolving regulatory and environmental requirements for next-generation agrochemicals.

Industry compliance standards

• FAO/WHO Specifications and Evaluations for Agricultural Pesticides
• OECD Principles of GLP
• Regulation (EC) No 1107/2009 for plant protection products

Typical usage ratio

• 0.5–1.3 molar equivalents per chiral intermediate synthesis; tuned per activity and metabolic stability of target ingredient

Downstream process integration

• Employed at chiral center formation or chain extension step, typically through amide or amine functionalization; subsequent Boc removal performed prior to final formulation

Final product types

• Stereopure pesticide intermediates
• Fungicide and herbicide actives with improved bioselectivity
• Chiral agricultural chemicals for formulation into EC, WP, or SC dosage forms

4. Intermediate for Custom Chemical Synthesis in Contract Manufacturing (CDMO/CMO)

Chemical development and manufacturing organizations incorporate our raw material into custom routes for small molecule projects, especially where chirality and protection are critical for scale-up. Developers apply our compound in multistep syntheses for investigational APIs and specialty compounds, often as a platform intermediate in confidential process packages. Our facility supports full traceability and analytical data sharing, meeting customer specifications for impurity profile and batch consistency. We adjust supply and specification in line with client regulatory filing requirements and future commercial launch scale-up.

Industry compliance standards

• cGMP (current Good Manufacturing Practices)
• ISO 14001 (Environmental Management for chemical production sites)
• Client-specific regulatory and quality system requirements, audit ready

Typical usage ratio

• 0.3–2.0 equivalents per batch, dependent on synthetic step, number of protection-deprotection cycles, and downstream conversion requirements

Downstream process integration

• Supplied at multi-kilo or pilot scale to custom synthesis sequences; enters via manual or automated reagent addition during protected amine installation, ring closure, or combinatorial library assembly

Final product types

• Small molecule pharmaceutical candidates
• Specialty chemicals for R&D and process validation
• Scale-up reference standards for regulatory submission